InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX Clue Score40
United States Fiscal year ends December CIK 0001658551 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

9
Insider
Date
Role
Action
Shares
Price
Amount
Justin B. Klee
16 Jan 2026
Co-Chief Executive Officer
Sold after exercise
1,995
$13.89
$27.70K
Joshua B Cohen
16 Jan 2026
Co-Chief Executive Officer
Sold after exercise
1,974
$13.83
$27.30K
Justin B. Klee
15 Jan 2026
Co-Chief Executive Officer
Sold after exercise
136,193
$13.58
$1.85M
Joshua B Cohen
15 Jan 2026
Co-Chief Executive Officer
Sold after exercise
136,193
$13.59
$1.85M
James M Frates
16 May 2023
Chief Financial Officer
Sold after exercise
500
$27.60
$13.80K
James M Frates
16 May 2023
Chief Financial Officer
Sold after exercise
32,000
$26.93
$861.65K
Patrick D Yeramian
15 May 2023
Chief Medical Officer
Sold after exercise
11,965
$29.03
$347.36K
Patrick D Yeramian
17 Apr 2023
Chief Medical Officer
Sold after exercise
300
$30.94
$9.28K
Patrick D Yeramian
17 Apr 2023
Chief Medical Officer
Sold after exercise
49,279
$30.53
$1.50M
Show all 162 transactions →

What was left out

Form 4 filings counted 178
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 9
Sales at will 117
Transactions with no price 0
Shares from compensation/vesting 38,287,796
Sales filed before the plan box existed 42
History held since 10 Jan 2022